Literature DB >> 15102077

Deficiency of tenascin-X causes abnormalities in dermal elastic fiber morphology.

Manon C Zweers1, Ivonne M van Vlijmen-Willems, Toin H van Kuppevelt, Robert P Mecham, Peter M Steijlen, Jim Bristow, Joost Schalkwijk.   

Abstract

Deficiency of the extracellular matrix protein tenascin-X (TNX) was recently described as the molecular basis of a new, recessive type of Ehlers-Danlos syndrome. Here we report gross abnormalities of the elastic fibers and microfibrils in the dermis of these patients, and reduced dermal collagen content, as determined by quantitative image analysis. The ascending, fine elastic fibers in the papillary dermis were absent or inconspicuous and had few branches. The coarse elastic fibers of the reticular dermis were fragmented and clumped. At the ultrastructural level, irregular and immature elastin fibers and fibers devoid of microfibrils were observed. In TNX-deficient patients the dermal collagen density was reduced, but no structural abnormalities in the collagen fibrils were found. These findings suggest that both elastic fiber abnormalities and reduced collagen content contribute to the observed phenotype in TNX-deficient patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102077     DOI: 10.1111/j.0022-202X.2004.22401.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

Review 1.  Ehlers-Danlos syndrome (EDS) type IV: review of the literature.

Authors:  Cristiano Macabu Badauy; Sabrina S Gomes; Manoel Sant'Ana Filho; José Artur Bogo Chies
Journal:  Clin Oral Investig       Date:  2007-01-13       Impact factor: 3.573

Review 2.  The contribution of natural selection to present-day susceptibility to chronic inflammatory and autoimmune disease.

Authors:  Jessica F Brinkworth; Luis B Barreiro
Journal:  Curr Opin Immunol       Date:  2014-10-22       Impact factor: 7.486

3.  Tenascin-X, collagen, and Ehlers-Danlos syndrome: tenascin-X gene defects can protect against adverse cardiovascular events.

Authors:  John W Petersen; J Yellowlees Douglas
Journal:  Med Hypotheses       Date:  2013-07-03       Impact factor: 1.538

Review 4.  A cytokine axis regulates elastin formation and degradation.

Authors:  Erin P Sproul; W Scott Argraves
Journal:  Matrix Biol       Date:  2012-11-13       Impact factor: 11.583

5.  Broadening the Spectrum of Ehlers Danlos Syndrome in Patients With Congenital Adrenal Hyperplasia.

Authors:  Rachel Morissette; Wuyan Chen; Ashley F Perritt; Jennifer L Dreiling; Andrew E Arai; Vandana Sachdev; Hwaida Hannoush; Ashwini Mallappa; Zhi Xu; Nazli B McDonnell; Martha Quezado; Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2015-06-15       Impact factor: 5.958

6.  Phenotypic effects of Ehlers-Danlos syndrome-associated mutation on the FnIII domain of tenascin-X.

Authors:  Shulin Zhuang; Apichart Linhananta; Hongbin Li
Journal:  Protein Sci       Date:  2010-10-02       Impact factor: 6.725

Review 7.  Vesicoureteral reflux and the extracellular matrix connection.

Authors:  Fatima Tokhmafshan; Patrick D Brophy; Rasheed A Gbadegesin; Indra R Gupta
Journal:  Pediatr Nephrol       Date:  2016-05-02       Impact factor: 3.714

8.  Analysis of obstetric complications and uterine connective tissue in tenascin-X-deficient humans and mice.

Authors:  David F Egging; Ivonne van Vlijmen-Willems; Jiwon Choi; Anita C T M Peeters; Desiree van Rens; Guido Veit; Manuel Koch; Elaine C Davis; Joost Schalkwijk
Journal:  Cell Tissue Res       Date:  2008-03-12       Impact factor: 5.249

Review 9.  Tenascin-X: beyond the architectural function.

Authors:  Ulrich Valcourt; Lindsay B Alcaraz; Jean-Yves Exposito; Claire Lethias; Laurent Bartholin
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

10.  Tenascin-X promotes epithelial-to-mesenchymal transition by activating latent TGF-β.

Authors:  Lindsay B Alcaraz; Jean-Yves Exposito; Nicolas Chuvin; Roxane M Pommier; Caroline Cluzel; Sylvie Martel; Stéphanie Sentis; Laurent Bartholin; Claire Lethias; Ulrich Valcourt
Journal:  J Cell Biol       Date:  2014-05-12       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.